Abstract
Early development of mechanical circulatory support was aimed at replacing the native ventricles by a total artificial heart (TAH). However, progress was limited by the constraints of the then-available technologies and let to a shift toward implantable left ventricular assist devices (LVADs), supporting the left heart only. Over time, LVADs underwent a technological metamorphosis from valve-containing large devices placed in extra-thoracic pump pockets to valveless rotary flow devices that can be placed directly in the thoracic cavity using less-invasive surgical techniques [1]. These rotary flow devices contain narrow gaps and mechanical or hydrodynamic bearings and produce continuous flow in a high-shear environment. Despite the use of high levels of anticoagulation, pump thrombosis, acquired von Willebrand factor deficiency, and gastrointestinal bleeding have been observed with the use of these devices, indicating poor hemocompatibility [2, 3]. In addition, 10–40% patients with advanced left ventricular dysfunction treated by LVADs develop right ventricular dysfunction, resulting in complications related to right-sided congestion, such as renal failure and right heart failure [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED et al (2015) Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant 34(12):1495–1504
Stulak JM, Lee D, Haft JW, Romano MA, Cowger JA, Park SJ et al (2014) Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 33(1):60–64
Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA et al (2014) Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 370(1):33–40
Kormos RL (2014) The right heart failure dilemma in the era of left ventricular assist devices. J Heart Lung Transplant 33(2):134–135
Copeland JG, Copeland H, Gustafson M, Mineburg N, Covington D, Smith RG et al (2012) Experience with more than 100 total artificial heart implants. J Thorac Cardiovasc Surg 143(3):727–734
Carpentier A (2007) The surprising rise of nonthrombogenic valvular surgery. Nat Med 13(10):1165–1168
Jansen P, van Oeveren W, Capel A, Carpentier A (2012) In vitro haemocompatibility of a novel bioprosthetic total artificial heart. Eur J Cardiothorac Surg 41(6):e166–e172
Latremouille C, Duveau D, Cholley B, Zilberstein L, Belbis G, Boughenou M et al (2015) Animal studies with the Carmat bioprosthetic total artificial heart. Eur J Cardiothorac Surg 47:e172–e1e9
Quader MA, Goodreau AM, Shah KB, Katlaps G, Cooke R, Smallfield MC et al (2016) Renal function recovery with total artificial heart support. ASAIO J 62(1):87–91
Stevenson L, Pagani F, Young JB, Jessup M, Miller L, Kormos R et al (2009) INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009(28):535–541
Carpentier A, Latrémouille C, Cholley B, Smadja DM, Roussel J-C, Boissier E et al (2015) First clinical use of a bioprosthetic total artificial heart: report of two cases. Lancet 386(10003):1556–1563
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Jansen, P., Latrémouille, C., Carpentier, A. (2017). Early Experience with the CARMAT Bioprosthetic Artificial Heart. In: Montalto, A., Loforte, A., Musumeci, F., Krabatsch, T., Slaughter, M. (eds) Mechanical Circulatory Support in End-Stage Heart Failure. Springer, Cham. https://doi.org/10.1007/978-3-319-43383-7_55
Download citation
DOI: https://doi.org/10.1007/978-3-319-43383-7_55
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43381-3
Online ISBN: 978-3-319-43383-7
eBook Packages: MedicineMedicine (R0)